瑞莎珠单抗治疗活动性银屑病关节炎的疗效与安全性:随机双盲3期KEEPsAKE 1试验24周结果
KEEPsAKE 1试验将964例对≥1种传统合成改善病情抗风湿药应答不足或不耐受的活动性银屑病关节炎患者按1:1随机分配至瑞莎珠单抗150mg组或安慰剂组,于第0、4、16周给药。第24周时瑞莎珠单抗组达到ACR20的比例显著高于安慰剂组(57.3% vs 33.5%,p<0.001),前8个排序次要终点也均显著优于安慰剂(p<0.001)。不良事件和严重不良事件发生率两组相似,瑞莎珠单抗组报告1例死亡(尿脓毒症,判定与试验药物无关)。
要点
- 第24周ACR20应答率瑞莎珠单抗组57.3% vs 安慰剂组33.5%,差异显著(p<0.001)。
- 皮肤和指甲银屑病、最低疾病活动度、附着点炎和指趾炎消退等前8个排序次要终点均显著优于安慰剂(p<0.001)。
- 不良事件和严重不良事件发生率两组相似,严重感染率瑞莎珠单抗组1.0% vs 安慰剂组1.2%,瑞莎珠单抗组1例死亡(尿脓毒症,判定与药物无关)。
核心结论
- 瑞莎珠单抗治疗活动性银屑病关节炎患者,较安慰剂显著改善体征和症状,且耐受性良好。
研究设计与样本
- 随机、安慰剂对照、双盲3期KEEPsAKE 1试验,纳入964例对≥1种传统合成改善病情抗风湿药应答不足或不耐受的活动性银屑病关节炎患者,按1:1随机分配至瑞莎珠单抗150mg组或安慰剂组,于第0、4、16周给药。
- 本次报告24周双盲期结果,所有患者均接受瑞莎珠单抗的开放标签期正在进行中。
主要发现
- 第24周达到ACR20的患者比例瑞莎珠单抗组为57.3%,安慰剂组为33.5%,差异显著(p<0.001)。
- 瑞莎珠单抗组在皮肤和指甲银屑病终点、最低疾病活动度、附着点炎和指趾炎消退等前8个排序次要终点上均显著优于安慰剂(p<0.001)。
- 不良事件和严重不良事件发生率在瑞莎珠单抗组与安慰剂组相似。
- 严重感染发生率瑞莎珠单抗组为1.0%,安慰剂组为1.2%。
- 瑞莎珠单抗组报告1例死亡(尿脓毒症,判定与试验药物无关)。
关键数值与推荐
- 主要终点为第24周达到美国风湿病学会标准≥20%改善(ACR20)的患者比例,瑞莎珠单抗组57.3% vs 安慰剂组33.5%(p<0.001)。
- 前8个排序次要终点(含皮肤和指甲银屑病终点、最低疾病活动度、附着点炎和指趾炎消退)瑞莎珠单抗组均显著优于安慰剂(p<0.001)。
- 严重感染率瑞莎珠单抗组1.0% vs 安慰剂组1.2%。
临床怎么用
- 对于对≥1种传统合成改善病情抗风湿药应答不足或不耐受的活动性银屑病关节炎患者,瑞莎珠单抗150mg于第0、4、16周给药可显著改善体征和症状,且耐受性良好(据原文结论)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate risankizumab, a biological therapy that inhibits interleukin 23, in patients with active psoriatic arthritis (PsA) who have responded inadequately or are intolerant to ≥1 conventional synthetic disease-modifying antirheumatic drug (csDMARD). METHODS: In the randomised, placebo-controlled, double-blind KEEPsAKE 1 trial, 964 patients with active PsA were randomised (1:1) to receive risankizumab 150 mg or placebo at weeks 0, 4 and 16. The primary endpoint was the proportion of patients achieving ≥20% improvement in American College of Rheumatology criteria (ACR20) at week 24. Here, we report the results from the 24-week double-blind period; the open-label period with all patients receiving risankizumab is ongoing. RESULTS: At week 24, a significantly greater proportion of patients receiving risankizumab achieved the primary endpoint of ACR20 (57.3% vs placebo, 33.5%; p<0.001). Significant differences were also observed for risankizumab versus placebo for the first eight ranked secondary endpoints, including skin and nail psoriasis endpoints, minimal disease activity and resolution of enthesitis and dactylitis (p<0.001). Adverse events and serious adverse events were reported at similar rates in the risankizumab and placebo groups. Serious infections were reported for 1.0% and 1.2% of patients receiving risankizumab and placebo, respectively. There was one death in the risankizumab group (urosepsis deemed unrelated to the study drug). CONCLUSIONS: Risankizumab treatment results in significantly greater improvement of signs and symptoms of PsA compared with placebo and is well tolerated in patients with active PsA who have responded inadequately or are intolerant to ≥1 csDMARD. TRIAL REGISTRATION NUMBER: NCT03675308.
引用
- Kristensen LE, Keiserman M, Papp K, et al. Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial. Ann Rheum Dis. 2021. PMID: 34911706. doi:10.1136/annrheumdis-2021-221019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。